alirocumab
Selected indexed studies
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. (JAMA, 2022) [PMID:35368058]
- Alirocumab: Pediatric First Approval. (Paediatr Drugs, 2024) [PMID:38874895]
- Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. (JAMA Pediatr, 2024) [PMID:38315470]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. (2022) pubmed
- Alirocumab: Pediatric First Approval. (2024) pubmed
- Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. (2024) pubmed
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. (2020) pubmed
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. (2015) pubmed
- Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome. (2024) pubmed
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. (2019) pubmed
- Alirocumab for low-density lipoprotein cholesterol lowering. (2019) pubmed
- Alirocumab for the treatment of hypercholesterolemia. (2017) pubmed
- Alirocumab versus Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis. (2026) pubmed